Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 33321-33330 Newer>

The Motley Fool December 4, 2008 Rick Aristotle Munarriz	5 Free Internet Winners Free nationwide connectivity is a vote -- and bid -- away. If free Wi-Fi comes to pass who will the biggest winners be?
The Motley Fool December 4, 2008	Today's 5-Star Movers A list of today's top movers from the Motley Fool five-star stock list.
The Motley Fool December 4, 2008 Tim Beyers	Apple Isn't a One-Hit Wonder While Apple has had its share of blunders, it certainly is not a one-hit wonder along the lines of no-longer independent Iomega.
The Motley Fool December 4, 2008 Brian D. Pacampara	5-Star Stocks Poised to Pop: Western Union Let's take a closer look at Western Union's business, and see why this stock is poised to outperform.
The Motley Fool December 4, 2008 Christopher Barker	Gold Selling for $10 an Ounce! The founder and CEO of Seabridge Gold announces to the mining industry that he is looking to sell his company to one of the majors.
Bank Systems & Technology December 3, 2008 Maria Bruno-Britz	Goldman Could Roll Out Direct Bank The former investment bank/now commercial bank would likely seek to increase its deposit base by offering a variety of savings products, such as certificates of deposits, online.
The Motley Fool December 3, 2008 Toby Shute	Buffett's New Buyout Battle France's EDF makes a fresh offer for 50% of Berkshire Hathaway's Constellation's nuclear business.
The Motley Fool December 3, 2008 Alex Dumortier	GAO to Paulson: Get Your TARP in Order The Government Accountability Office chides the Treasury Department for failing to address a number of key issues with respect to the Troubled Asset Relief Program.
The Motley Fool December 3, 2008 David Lee Smith	Dow Chemical's Nimble New Moves With its Kuwait venture saved and a solid acquisition, Dow Chemical is one to keep an eye on.
The Motley Fool December 3, 2008 Brian Orelli	High-Margin Generic Drugmakers -- An Oxymoron? The big profits come when a generic-drug maker doesn't have any competition.
<Older 33321-33330 Newer> Return to current articles.